Name | Value |
---|---|
Revenues | 81.0K |
Cost of Revenue | 3.0K |
Gross Profit | 78.0K |
Operating Expense | 1,928.0K |
Operating I/L | -1,931.0K |
Other Income/Expense | -39.0K |
Interest Income | 0.0K |
Pretax | -1,970.0K |
Income Tax Expense | 1,750.0K |
Net Income/Loss | -1,970.0K |
Titan Pharmaceuticals, Inc. is a pharmaceutical company specializing in therapeutics for chronic diseases. The company's primary revenue-generating product is Probuphine, an implant for the maintenance treatment of opioid use disorder. Additionally, Titan is developing a range of products utilizing its ProNeura drug delivery platform, including a kappa opioid agonist peptide program for chronic pruritus, a nalmefene implant program for opioid relapse prevention, and other programs such as HIV preventative therapeutics and a contraceptive implant. These products form the core of Titan's business, leveraging its proprietary technology to address unmet medical needs and generate revenue.